These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25568297)

  • 1. Triheptanoin improves brain energy metabolism in patients with Huntington disease.
    Adanyeguh IM; Rinaldi D; Henry PG; Caillet S; Valabregue R; Durr A; Mochel F
    Neurology; 2015 Feb; 84(5):490-5. PubMed ID: 25568297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency.
    Mochel F; Hainque E; Gras D; Adanyeguh IM; Caillet S; Héron B; Roubertie A; Kaphan E; Valabregue R; Rinaldi D; Vuillaumier S; Schiffmann R; Ottolenghi C; Hogrel JY; Servais L; Roze E
    J Neurol Neurosurg Psychiatry; 2016 May; 87(5):550-3. PubMed ID: 26536893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triheptanoin for the treatment of brain energy deficit: A 14-year experience.
    Mochel F
    J Neurosci Res; 2017 Nov; 95(11):2236-2243. PubMed ID: 28688166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy.
    Lodi R; Schapira AH; Manners D; Styles P; Wood NW; Taylor DJ; Warner TT
    Ann Neurol; 2000 Jul; 48(1):72-6. PubMed ID: 10894218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington's disease.
    Mochel F; Duteil S; Marelli C; Jauffret C; Barles A; Holm J; Sweetman L; Benoist JF; Rabier D; Carlier PG; Durr A
    Eur J Hum Genet; 2010 Sep; 18(9):1057-60. PubMed ID: 20512158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bio-energetic impairment in human calf muscle in thyroid disorders: a 31P MRS study.
    Khushu S; Rana P; Sekhri T; Sripathy G; Tripathi RP
    Magn Reson Imaging; 2010 Jun; 28(5):683-9. PubMed ID: 20332062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal response to cortical activation in early stages of Huntington disease.
    Mochel F; N'Guyen TM; Deelchand D; Rinaldi D; Valabregue R; Wary C; Carlier PG; Durr A; Henry PG
    Mov Disord; 2012 Jun; 27(7):907-10. PubMed ID: 22517114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanded neurochemical profile in the early stage of Huntington disease using proton magnetic resonance spectroscopy.
    Adanyeguh IM; Monin ML; Rinaldi D; Freeman L; Durr A; Lehéricy S; Henry PG; Mochel F
    NMR Biomed; 2018 Mar; 31(3):. PubMed ID: 29315899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study.
    Tabrizi SJ; Blamire AM; Manners DN; Rajagopalan B; Styles P; Schapira AH; Warner TT
    Neurology; 2005 May; 64(9):1655-6. PubMed ID: 15883340
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease.
    Kasparová S; Sumbalová Z; Bystrický P; Kucharská J; Liptaj T; Mlynárik V; Gvozdjáková A
    Neurochem Int; 2006 Jan; 48(2):93-9. PubMed ID: 16290265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression.
    Mochel F; Charles P; Seguin F; Barritault J; Coussieu C; Perin L; Le Bouc Y; Gervais C; Carcelain G; Vassault A; Feingold J; Rabier D; Durr A
    PLoS One; 2007 Jul; 2(7):e647. PubMed ID: 17653274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of dynamic ³¹P magnetic resonance spectroscopy technique in in vivo assessment of the skeletal muscle mitochondrial function in type 2 diabetes.
    Wu FY; Tu HJ; Qin B; Chen T; Xu HF; Qi J; Wang DH
    Chin Med J (Engl); 2012 Jan; 125(2):281-6. PubMed ID: 22340560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington's disease provides in vivo evidence for impaired energy metabolism.
    van den Bogaard SJ; Dumas EM; Teeuwisse WM; Kan HE; Webb A; Roos RA; van der Grond J
    J Neurol; 2011 Dec; 258(12):2230-9. PubMed ID: 21614431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10.
    Koroshetz WJ; Jenkins BG; Rosen BR; Beal MF
    Ann Neurol; 1997 Feb; 41(2):160-5. PubMed ID: 9029064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease.
    Esmaeilzadeh M; Kullingsjö J; Ullman H; Varrone A; Tedroff J
    Clin Neuropharmacol; 2011; 34(3):95-100. PubMed ID: 21586914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is brain lactate increased in Huntington's disease?
    Martin WR; Wieler M; Hanstock CC
    J Neurol Sci; 2007 Dec; 263(1-2):70-4. PubMed ID: 17655868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic disturbances during short exercises in dermatomyositis revealed by real-time functional 31P magnetic resonance spectroscopy.
    Pfleiderer B; Lange J; Loske KD; Sunderkötter C
    Rheumatology (Oxford); 2004 Jun; 43(6):696-703. PubMed ID: 15054156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement.
    Pascual JM; Liu P; Mao D; Kelly DI; Hernandez A; Sheng M; Good LB; Ma Q; Marin-Valencia I; Zhang X; Park JY; Hynan LS; Stavinoha P; Roe CR; Lu H
    JAMA Neurol; 2014 Oct; 71(10):1255-65. PubMed ID: 25110966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homeostatic adaptations in brain energy metabolism in mouse models of Huntington disease.
    Tkac I; Henry PG; Zacharoff L; Wedel M; Gong W; Deelchand DK; Li T; Dubinsky JM
    J Cereb Blood Flow Metab; 2012 Nov; 32(11):1977-88. PubMed ID: 22805874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal metabolite changes in Huntington's disease during disease onset.
    van den Bogaard SJ; Dumas EM; Teeuwisse WM; Kan HE; Webb A; van Buchem MA; Roos RA; van der Grond J
    J Huntingtons Dis; 2014; 3(4):377-86. PubMed ID: 25575959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.